# Nidan Lab (NSE: NIDAN) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/NIDAN · Pivot · prices to 21 Oct 2026

Nidan Lab (NSE: NIDAN) closed at ₹12.65 on 21 Oct 2026. With a market capitalisation of ₹18 Cr, it ranks 3630th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.

Its return on equity was 2.9% in FY25. Over the past year the share price has fallen 31.3%. Its 52-week range is ₹11.50 (25 Jun 2026) to ₹24.90 (1 Dec 2025); the last close is 49.2% below the high. Promoters held 57.04% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹12.65 |
| Market cap | ₹18 Cr |
| ROE | 2.9% (FY25) |
| ROCE | 6.7% (FY25) |
| Debt to equity | 0.16 |
| 52-week high | ₹24.90 (1 Dec 2025) |
| 52-week low | ₹11.50 (25 Jun 2026) |
| 1-year return | −31.3% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹25 Cr | ₹2 Cr |
| FY24 | ₹24 Cr | −₹3 Cr |
| FY23 | ₹24 Cr | ₹4 Cr |
| FY22 | ₹30 Cr | ₹3 Cr |
| FY21 | ₹20 Cr | ₹2 Cr |
| FY20 | ₹22 Cr | ₹1 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 57.04%
- Non-institutions: 42.96%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Adeshwar Medite](https://app.pivotnow.in/stock/ADESHWAR) | — | ₹21 Cr | — | — |
| [Maitri](https://app.pivotnow.in/stock/MAITRI) | — | ₹19 Cr | — | — |
| [Desh Rakshak](https://app.pivotnow.in/stock/DESHRAK) | — | ₹19 Cr | — | — |
| [Vanta Bioscienc](https://app.pivotnow.in/stock/VANTABIO) | — | ₹17 Cr | — | — |
| [Venmax Drugs](https://app.pivotnow.in/stock/VENMAX) | — | ₹17 Cr | — | — |
| [Zenith Health](https://app.pivotnow.in/stock/ZENITHHE) | — | ₹17 Cr | — | — |

## Questions and answers

### What is the share price of Nidan Lab today?

Nidan Lab (NSE: NIDAN) last closed at ₹12.65 on 21 Oct 2026. Its 52-week high is ₹24.90 and its 52-week low is ₹11.50.

### What is the market cap of Nidan Lab?

Nidan Lab's market capitalisation is ₹18 Cr (₹18 Cr) at the 22 Oct 2026 close, ranking 3630th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Nidan Lab?

Return on equity was 2.9% in FY25 and return on capital employed was 6.7% in FY25 (standalone figures).

### Is Nidan Lab a debt-free company?

No. Nidan Lab's debt-to-equity ratio was 0.16 in FY25, with total debt of ₹4 Cr.

### How has Nidan Lab stock performed over the last year?

Nidan Lab's share price has fallen 31.3% over the past year, −7.0% over three months and −6.3% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Nidan Lab?

As of 30 Jun 2026: promoters 57.04%, non-institutions 42.96%.

### Who are Nidan Lab's competitors?

The listed Pharma & Healthcare companies closest to Nidan Lab by market cap are Adeshwar Medite, Maitri, Desh Rakshak, Vanta Bioscienc, Venmax Drugs and Zenith Health.

### Is Nidan Lab a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Nidan Lab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NIDAN against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.